Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast cancer subjects.
Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Colorectal Cancer|Metastatic Lung Cancer
DRUG: OBI-833/OBI-821
Number of Participants With Treatment-emergent Adverse Events, Approximately 13 weeks for dose escalation cohorts and 44 weeks for expansion cohort
Maximal Post-baseline Anti-Globo H Antibody Responses, Anti-Globo H IgM and IgG concentrations were measured using a chemical binding assay., Approximately 13 weeks for dose escalation cohorts and 44 weeks for expansion cohort
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast cancer subjects.